Nuclear Imaging Equipment Market - forecast to 2033 : By TECHNOLOGY (SPECT, PET, Planar Scintigraphy, Hybrid Imaging), APPLICATION (Oncology, Cardiology, Neurology, Orthopedics, Urology, Gastroenterology, Others), END-USER (Hospitals, Imaging Centers, Aca

Nuclear Imaging Equipment Market - forecast to 2033 : By TECHNOLOGY (SPECT, PET, Planar Scintigraphy, Hybrid Imaging), APPLICATION (Oncology, Cardiology, Neurology, Orthopedics, Urology, Gastroenterology, Others), END-USER (Hospitals, Imaging Centers, Academic and Research Institutes, Pharmaceutical Companies, Others), RADIOPHARMACEUTICS (Technetium-99m, Fluorodeoxyglucose, Rubidium-82, Others), DETECTOR TYPE (Scintillation Detectors, Solid-State Detectors), MODALITY (Fixed Systems, Portable Systems), COMPONENT (Hardware, Software, Services), and Region


The Nuclear Imaging Equipment Market encompasses a range of advanced medical devices used for diagnostic and therapeutic procedures. These devices employ radioactive substances, known as radiotracers, to visualize and assess the function of various body systems, including the heart, brain, and other organs.

The Nuclear Imaging Equipment Market, market size was USD 2.7 Billion in 2023, and it is anticipated to grow to over 4.83 Billion by 2033, at a CAGR of over 5.4% during the forecast period.

The nuclear imaging equipment market is propelled by the rising prevalence of chronic diseases and advancements in technology that emphasize early and accurate disease detection. Innovations in Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) scanners, among others, are pivotal in providing detailed molecular-level images of the body's internal structures. This technological sophistication supports the diagnosis and monitoring of various conditions, including cancer, cardiovascular diseases, and neurological disorders. Furthermore, the stringent regulatory environment ensures that only high-quality, safe equipment is used, reinforcing the market's growth driven by increasing demand for early disease detection and precise diagnostics.

Key Trends:
  • Technological Advancements: Rapid progress in technology is leading to the development of more efficient and accurate nuclear imaging equipment.
  • Increased Demand in Oncology: The rising prevalence of cancer globally is driving the demand for nuclear imaging in oncology for accurate diagnosis and treatment.
  • Adoption of AI and Machine Learning: The integration of AI and machine learning in nuclear imaging is improving the precision and speed of diagnosis.
  • Growth in Geriatric Population: The increasing aging population worldwide is contributing to the growth of the nuclear imaging equipment market due to the higher incidence of chronic diseases in this demographic.
  • Regulatory Support and Funding: Governments and regulatory bodies are providing support and funding for the development and adoption of nuclear imaging technologies..
Key Drivers:
  • Technological Advancements: Continuous innovation and development of high-performance imaging equipment.
  • Aging Population: The increasing number of elderly people worldwide, leading to a higher demand for diagnostic procedures.
  • Prevalence of Chronic Diseases: Rising incidence of cancer and cardiovascular diseases requiring nuclear imaging for diagnosis and treatment.
  • Increase in Healthcare Expenditure: Growing investment in healthcare infrastructure and services, especially in developing countries.
  • Government Initiatives: Supportive government policies and funding for research and development in nuclear imaging technologies.
Restraints and Challenges:
  • High Cost of Equipment: The high initial cost of nuclear imaging equipment can be a significant barrier for many healthcare providers, particularly in developing countries.
  • Regulatory Hurdles: Strict regulations and lengthy approval processes can delay the introduction of new equipment into the market.
  • Shortage of Radiopharmaceuticals: The production and supply of radiopharmaceuticals, which are crucial for nuclear imaging, can be inconsistent, affecting the market growth.
  • Lack of Trained Professionals: The complexity of nuclear imaging equipment requires highly trained professionals for operation and interpretation, which are often in short supply.
  • Radiation Exposure Concerns: Despite the benefits of nuclear imaging, concerns about radiation exposure can deter patients and healthcare providers from using this technology...
Segmentation:

TECHNOLOGY (SPECT, PET, Planar Scintigraphy, Hybrid Imaging), APPLICATION (Oncology, Cardiology, Neurology, Orthopedics, Urology, Gastroenterology, Others), END-USER (Hospitals, Imaging Centers, Academic and Research Institutes, Pharmaceutical Companies, Others), RADIOPHARMACEUTICS (Technetium-99m, Fluorodeoxyglucose, Rubidium-82, Others), DETECTOR TYPE (Scintillation Detectors, Solid-State Detectors), MODALITY (Fixed Systems, Portable Systems), COMPONENT (Hardware, Software, Services), and Region

Key Players:

The Nuclear Imaging Equipment Market includes players such as GE Healthcare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems, Hitachi Medical, Neusoft Medical Systems, Mediso Medical Imaging Systems, DDD-Diagnostics, SurgicEye, CMR Naviscan Kromek Group, Gamma Medica, Capintec, Toshiba, Biosensors International, Blue Earth Diagnostics, Cardinal Health, Digirad Corporation, Eczacibasi-Monrol, and Fujifilm Holdings, among others.

Value Chain Analysis:

The value chain analysis for the Nuclear Imaging Equipment Market can be delineated into five pivotal stages: Raw Material Procurement, R&D, Product Approval, Large Scale Manufacturing, and Sales and Marketing. Each stage plays a crucial role in ensuring the seamless progression from concept to market-ready product, while also ensuring compliance, quality, and market competitiveness. Below is a detailed analysis of each stage:
  • Raw Material Procurement: Identify sources of raw materials, assess their availability, quality, and sustainability. Understanding market dynamics, pricing trends, and potential risks associated with sourcing materials is crucial. This involves establishing robust relationships with suppliers, ensuring ethical sourcing practices, and maintaining a steady supply chain to avoid disruptions. Additionally, the procurement process must consider the specific requirements for high-purity materials and components necessary for nuclear imaging equipment.
  • R&D (Research and Development): R&D focuses on market analysis, trend forecasting, feasibility studies, and conducting experiments to develop new products or enhance existing ones. In the context of nuclear imaging equipment, this includes innovating cutting-edge imaging technologies, improving resolution and accuracy, and integrating advanced software for image processing. Collaboration with academic institutions, leveraging grants and funding, and protecting intellectual property through patents are also critical components of this stage.
  • Product Approval: Understanding legal requirements, industry regulations, and certification processes is paramount. This stage involves rigorous testing of products for safety, efficacy, and environmental impact. Compliance with international standards such as FDA (Food and Drug Administration) approval in the US, CE marking in Europe, and other regional regulatory bodies is essential. Additionally, conducting clinical trials, gathering empirical data, and ensuring adherence to radiation safety standards are key activities.
  • Large Scale Manufacturing: Optimizing production processes, improving efficiency, and reducing costs are the primary objectives. This includes process engineering, automation technologies, and supply chain management to enhance productivity and quality. For nuclear imaging equipment, maintaining precision and consistency in manufacturing is critical. Quality control measures, lean manufacturing principles, and continuous improvement practices help in minimizing defects and ensuring high-quality output. Strategic partnerships with component manufacturers and investing in state-of-the-art manufacturing facilities are also vital.
  • Sales and Marketing: Understanding customer needs, market trends, and competitive landscape is essential for effective sales and marketing. This involves market segmentation, consumer behavior analysis, and branding strategies to position the product effectively. Developing strong relationships with healthcare providers, hospitals, and diagnostic centers, as well as participating in industry conferences and trade shows, can enhance market penetration. Digital marketing, content creation, and leveraging social media platforms to educate potential customers and highlight product benefits are also crucial strategies. Furthermore, providing excellent after-sales support and training for end-users ensures customer satisfaction and loyalty..
Research Scope:
  • Estimates and forecast the overall market size for the total market, across type, application, and region
  • Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling
  • Identify factors influencing market growth and challenges, opportunities, drivers, and restraints
  • Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates
  • Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
  • Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market
  • To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements
  • Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives.
Our research report offers comprehensive deep segmental analysis, local competitive insights, and market positioning tailored to your needs. It includes detailed local market analysis and company analysis, alongside SWOT assessments to identify strengths, weaknesses, opportunities, and threats. The report is enhanced with an Excel data dashboard for seamless analytics and efficient data crunching, providing a user-friendly interface for in-depth examination. This robust toolkit empowers businesses to make informed decisions, stay ahead of competitors, and strategically position themselves in the market.”


Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.


1.0: MARKET DEFINITION
1.1: MARKET SEGMENTATION
1.2: REGIONAL COVERAGE
1.3: KEY COMPANY PROFILES
1.4: DATA SNAPSHOT
2.0: SUMMARY
2.1: KEY OPINION LEADERS
2.2: KEY HIGHLIGHTS BY TECHNOLOGY
2.3: KEY HIGHLIGHTS BY APPLICATION
2.4: KEY HIGHLIGHTS BY END-USER
2.5: KEY HIGHLIGHTS BY RADIOPHARMACEUTICS
2.6: KEY HIGHLIGHTS BY DETECTOR TYPE
2.7: KEY HIGHLIGHTS BY MODALITY
2.8: KEY HIGHLIGHTS BY COMPONENT
2.9: KEY HIGHLIGHTS BY REGION
2.10: KEY HIGHLIGHTS BY NORTH AMERICA
2.11: KEY HIGHLIGHTS BY LATIN AMERICA
2.12: KEY HIGHLIGHTS BY EUROPE
2.13: KEY HIGHLIGHTS BY ASIA/PACIFIC
2.14: KEY HIGHLIGHTS BY MIDDLE EAST/AFRICA
3.0: MARKET ATTRACTIVENESS ANALYSIS BY TECHNOLOGY
3.1: MARKET ATTRACTIVENESS ANALYSIS BY APPLICATION
3.2: MARKET ATTRACTIVENESS ANALYSIS BY END-USER
3.3: MARKET ATTRACTIVENESS ANALYSIS BY RADIOPHARMACEUTICS
3.4: MARKET ATTRACTIVENESS ANALYSIS BY DETECTOR TYPE
3.5: MARKET ATTRACTIVENESS ANALYSIS BY MODALITY
3.6: MARKET ATTRACTIVENESS ANALYSIS BY COMPONENT
3.7: MARKET ATTRACTIVENESS ANALYSIS BY REGION
3.8: MARKET ATTRACTIVENESS ANALYSIS BY COUNTRY
4.0: MARKET TRENDS
4.1: MARKET DRIVERS
4.2: MARKET OPPORTUNITIES
4.3: MARKET RESTRAINTS
4.4: MARKET THREATS
4.5: IMPACT ANALYSIS
5.0: PORTERS FIVE FORCES
5.1: ANSOFF MATRIX
5.2: PESTLE ANALYSIS
5.3: VALUE CHAIN ANALYSIS
6.0: IMPACT OF COVID-19 ON MARKET
7.0: IMPACT OF RUSSIA-UKRAINE WAR
8.0: PARENT MARKET ANALYSIS
8.1: REGULATORY LANDSCAPE
8.2: PRICING ANALYSIS
8.3: DEMAND SUPPLY ANALYSIS
8.4: DEMAND SUPPLY ANALYSIS
8.5: CONSUMER BUYING INTEREST
8.6: CONSUMER BUYING INTEREST
8.7: SUPPLY CHAIN ANALYSIS
8.8: COMPETITION PRODUCT ANALYSIS BY MANUFACTURER
8.9: TECHNOLOGICAL ADVANCEMENTS
8.10: RECENT DEVELOPMENTS
8.11: CASE STUDIES
9.0: MARKET SIZE AND FORECAST – BY VALUE
9.1: MARKET SIZE AND FORECAST – BY VOLUME
10.0: TECHNOLOGY OVERVIEW
10.1: MARKET SIZE AND FORECAST – BY TECHNOLOGY
10.2: SPECT OVERVIEW
10.3: SPECT BY REGION
10.4: SPECT BY COUNTRY
10.5: PET OVERVIEW
10.6: PET BY REGION
10.7: PET BY COUNTRY
10.8: PLANAR SCINTIGRAPHY OVERVIEW
10.9: PLANAR SCINTIGRAPHY BY REGION
10.10: PLANAR SCINTIGRAPHY BY COUNTRY
10.11: HYBRID IMAGING OVERVIEW
10.12: HYBRID IMAGING BY REGION
10.13: HYBRID IMAGING BY COUNTRY
11.0: APPLICATION OVERVIEW
11.1: MARKET SIZE AND FORECAST – BY APPLICATION
11.2: ONCOLOGY OVERVIEW
11.3: ONCOLOGY BY REGION
11.4: ONCOLOGY BY COUNTRY
11.5: CARDIOLOGY OVERVIEW
11.6: CARDIOLOGY BY REGION
11.7: CARDIOLOGY BY COUNTRY
11.8: NEUROLOGY OVERVIEW
11.9: NEUROLOGY BY REGION
11.10: NEUROLOGY BY COUNTRY
11.11: ORTHOPEDICS OVERVIEW
11.12: ORTHOPEDICS BY REGION
11.13: ORTHOPEDICS BY COUNTRY
11.14: UROLOGY OVERVIEW
11.15: UROLOGY BY REGION
11.16: UROLOGY BY COUNTRY
11.17: GASTROENTEROLOGY OVERVIEW
11.18: GASTROENTEROLOGY BY REGION
11.19: GASTROENTEROLOGY BY COUNTRY
11.20: OTHERS OVERVIEW
11.21: OTHERS BY REGION
11.22: OTHERS BY COUNTRY
12.0: END-USER OVERVIEW
12.1: MARKET SIZE AND FORECAST – BY END-USER
12.2: HOSPITALS OVERVIEW
12.3: HOSPITALS BY REGION
12.4: HOSPITALS BY COUNTRY
12.5: IMAGING CENTERS OVERVIEW
12.6: IMAGING CENTERS BY REGION
12.7: IMAGING CENTERS BY COUNTRY
12.8: ACADEMIC AND RESEARCH INSTITUTES OVERVIEW
12.9: ACADEMIC AND RESEARCH INSTITUTES BY REGION
12.10: ACADEMIC AND RESEARCH INSTITUTES BY COUNTRY
12.11: PHARMACEUTICAL COMPANIES OVERVIEW
12.12: PHARMACEUTICAL COMPANIES BY REGION
12.13: PHARMACEUTICAL COMPANIES BY COUNTRY
12.14: OTHERS OVERVIEW
12.15: OTHERS BY REGION
12.16: OTHERS BY COUNTRY
13.0: RADIOPHARMACEUTICS OVERVIEW
13.1: MARKET SIZE AND FORECAST – BY RADIOPHARMACEUTICS
13.2: TECHNETIUM-99M OVERVIEW
13.3: TECHNETIUM-99M BY REGION
13.4: TECHNETIUM-99M BY COUNTRY
13.5: FLUORODEOXYGLUCOSE OVERVIEW
13.6: FLUORODEOXYGLUCOSE BY REGION
13.7: FLUORODEOXYGLUCOSE BY COUNTRY
13.8: RUBIDIUM-82 OVERVIEW
13.9: RUBIDIUM-82 BY REGION
13.10: RUBIDIUM-82 BY COUNTRY
13.11: OTHERS OVERVIEW
13.12: OTHERS BY REGION
13.13: OTHERS BY COUNTRY
14.0: DETECTOR TYPE OVERVIEW
14.1: MARKET SIZE AND FORECAST – BY DETECTOR TYPE
14.2: SCINTILLATION DETECTORS OVERVIEW
14.3: SCINTILLATION DETECTORS BY REGION
14.4: SCINTILLATION DETECTORS BY COUNTRY
14.5: SOLID-STATE DETECTORS OVERVIEW
14.6: SOLID-STATE DETECTORS BY REGION
14.7: SOLID-STATE DETECTORS BY COUNTRY
15.0: MODALITY OVERVIEW
15.1: MARKET SIZE AND FORECAST – BY MODALITY
15.2: FIXED SYSTEMS OVERVIEW
15.3: FIXED SYSTEMS BY REGION
15.4: FIXED SYSTEMS BY COUNTRY
15.5: PORTABLE SYSTEMS OVERVIEW
15.6: PORTABLE SYSTEMS BY REGION
15.7: PORTABLE SYSTEMS BY COUNTRY
16.0: COMPONENT OVERVIEW
16.1: MARKET SIZE AND FORECAST – BY COMPONENT
16.2: HARDWARE OVERVIEW
16.3: HARDWARE BY REGION
16.4: HARDWARE BY COUNTRY
16.5: SOFTWARE OVERVIEW
16.6: SOFTWARE BY REGION
16.7: SOFTWARE BY COUNTRY
16.8: SERVICES OVERVIEW
16.9: SERVICES BY REGION
16.10: SERVICES BY COUNTRY
17.0: REGION OVERVIEW
17.1: MARKET SIZE AND FORECAST - BY REGION
17.2: NORTH AMERICA OVERVIEW
17.3: NORTH AMERICA BY COUNTRY
17.4: UNITED STATES OVERVIEW
17.5: UNITED STATES OVERVIEW
17.6: UNITED STATES OVERVIEW
17.7: UNITED STATES OVERVIEW
17.8: UNITED STATES OVERVIEW
17.9: UNITED STATES OVERVIEW
17.10: UNITED STATES OVERVIEW
17.11: UNITED STATES OVERVIEW
17.12: LOCAL MARKET ANALYSIS - UNITED STATES
17.13: CANADA OVERVIEW
17.14: CANADA OVERVIEW
17.15: CANADA OVERVIEW
17.16: CANADA OVERVIEW
17.17: CANADA OVERVIEW
17.18: CANADA OVERVIEW
17.19: CANADA OVERVIEW
17.20: CANADA OVERVIEW
17.21: LOCAL MARKET ANALYSIS - CANADA
17.22: LATIN AMERICA OVERVIEW
17.23: LATIN AMERICA BY COUNTRY
17.24: MEXICO OVERVIEW
17.25: MEXICO OVERVIEW
17.26: MEXICO OVERVIEW
17.27: MEXICO OVERVIEW
17.28: MEXICO OVERVIEW
17.29: MEXICO OVERVIEW
17.30: MEXICO OVERVIEW
17.31: MEXICO OVERVIEW
17.32: LOCAL MARKET ANALYSIS - MEXICO
17.33: BRAZIL OVERVIEW
17.34: BRAZIL OVERVIEW
17.35: BRAZIL OVERVIEW
17.36: BRAZIL OVERVIEW
17.37: BRAZIL OVERVIEW
17.38: BRAZIL OVERVIEW
17.39: BRAZIL OVERVIEW
17.40: BRAZIL OVERVIEW
17.41: LOCAL MARKET ANALYSIS - BRAZIL
17.42: ARGENTINA OVERVIEW
17.43: ARGENTINA OVERVIEW
17.44: ARGENTINA OVERVIEW
17.45: ARGENTINA OVERVIEW
17.46: ARGENTINA OVERVIEW
17.47: ARGENTINA OVERVIEW
17.48: ARGENTINA OVERVIEW
17.49: ARGENTINA OVERVIEW
17.50: LOCAL MARKET ANALYSIS - ARGENTINA
17.51: REST OF LATAM OVERVIEW
17.52: REST OF LATAM OVERVIEW
17.53: REST OF LATAM OVERVIEW
17.54: REST OF LATAM OVERVIEW
17.55: REST OF LATAM OVERVIEW
17.56: REST OF LATAM OVERVIEW
17.57: REST OF LATAM OVERVIEW
17.58: REST OF LATAM OVERVIEW
17.59: LOCAL MARKET ANALYSIS - REST OF LATAM
17.60: EUROPE OVERVIEW
17.61: EUROPE BY COUNTRY
17.62: GERMANY OVERVIEW
17.63: GERMANY OVERVIEW
17.64: GERMANY OVERVIEW
17.65: GERMANY OVERVIEW
17.66: GERMANY OVERVIEW
17.67: GERMANY OVERVIEW
17.68: GERMANY OVERVIEW
17.69: GERMANY OVERVIEW
17.70: LOCAL MARKET ANALYSIS - GERMANY
17.71: FRANCE OVERVIEW
17.72: FRANCE OVERVIEW
17.73: FRANCE OVERVIEW
17.74: FRANCE OVERVIEW
17.75: FRANCE OVERVIEW
17.76: FRANCE OVERVIEW
17.77: FRANCE OVERVIEW
17.78: FRANCE OVERVIEW
17.79: LOCAL MARKET ANALYSIS - FRANCE
17.80: UNITED KINGDOM OVERVIEW
17.81: UNITED KINGDOM OVERVIEW
17.82: UNITED KINGDOM OVERVIEW
17.83: UNITED KINGDOM OVERVIEW
17.84: UNITED KINGDOM OVERVIEW
17.85: UNITED KINGDOM OVERVIEW
17.86: UNITED KINGDOM OVERVIEW
17.87: UNITED KINGDOM OVERVIEW
17.88: LOCAL MARKET ANALYSIS - UNITED KINGDOM
17.89: RUSSIA OVERVIEW
17.90: RUSSIA OVERVIEW
17.91: RUSSIA OVERVIEW
17.92: RUSSIA OVERVIEW
17.93: RUSSIA OVERVIEW
17.94: RUSSIA OVERVIEW
17.95: RUSSIA OVERVIEW
17.96: RUSSIA OVERVIEW
17.97: LOCAL MARKET ANALYSIS - RUSSIA
17.98: SPAIN OVERVIEW
17.99: SPAIN OVERVIEW
17.100: SPAIN OVERVIEW
17.101: SPAIN OVERVIEW
17.102: SPAIN OVERVIEW
17.103: SPAIN OVERVIEW
17.104: SPAIN OVERVIEW
17.105: SPAIN OVERVIEW
17.106: LOCAL MARKET ANALYSIS - SPAIN
17.107: ITALY OVERVIEW
17.108: ITALY OVERVIEW
17.109: ITALY OVERVIEW
17.110: ITALY OVERVIEW
17.111: ITALY OVERVIEW
17.112: ITALY OVERVIEW
17.113: ITALY OVERVIEW
17.114: ITALY OVERVIEW
17.115: LOCAL MARKET ANALYSIS - ITALY
17.116: NETHERLANDS OVERVIEW
17.117: NETHERLANDS OVERVIEW
17.118: NETHERLANDS OVERVIEW
17.119: NETHERLANDS OVERVIEW
17.120: NETHERLANDS OVERVIEW
17.121: NETHERLANDS OVERVIEW
17.122: NETHERLANDS OVERVIEW
17.123: NETHERLANDS OVERVIEW
17.124: LOCAL MARKET ANALYSIS - NETHERLANDS
17.125: ISRAEL OVERVIEW
17.126: ISRAEL OVERVIEW
17.127: ISRAEL OVERVIEW
17.128: ISRAEL OVERVIEW
17.129: ISRAEL OVERVIEW
17.130: ISRAEL OVERVIEW
17.131: ISRAEL OVERVIEW
17.132: ISRAEL OVERVIEW
17.133: LOCAL MARKET ANALYSIS - ISRAEL
17.134: TURKEY OVERVIEW
17.135: TURKEY OVERVIEW
17.136: TURKEY OVERVIEW
17.137: TURKEY OVERVIEW
17.138: TURKEY OVERVIEW
17.139: TURKEY OVERVIEW
17.140: TURKEY OVERVIEW
17.141: TURKEY OVERVIEW
17.142: LOCAL MARKET ANALYSIS - TURKEY
17.143: REST OF EUROPE OVERVIEW
17.144: REST OF EUROPE OVERVIEW
17.145: REST OF EUROPE OVERVIEW
17.146: REST OF EUROPE OVERVIEW
17.147: REST OF EUROPE OVERVIEW
17.148: REST OF EUROPE OVERVIEW
17.149: REST OF EUROPE OVERVIEW
17.150: REST OF EUROPE OVERVIEW
17.151: LOCAL MARKET ANALYSIS - REST OF EUROPE
17.152: ASIA/PACIFIC OVERVIEW
17.153: ASIA/PACIFIC BY COUNTRY
17.154: CHINA OVERVIEW
17.155: CHINA OVERVIEW
17.156: CHINA OVERVIEW
17.157: CHINA OVERVIEW
17.158: CHINA OVERVIEW
17.159: CHINA OVERVIEW
17.160: CHINA OVERVIEW
17.161: CHINA OVERVIEW
17.162: LOCAL MARKET ANALYSIS - CHINA
17.163: INDIA OVERVIEW
17.164: INDIA OVERVIEW
17.165: INDIA OVERVIEW
17.166: INDIA OVERVIEW
17.167: INDIA OVERVIEW
17.168: INDIA OVERVIEW
17.169: INDIA OVERVIEW
17.170: INDIA OVERVIEW
17.171: LOCAL MARKET ANALYSIS - INDIA
17.172: JAPAN OVERVIEW
17.173: JAPAN OVERVIEW
17.174: JAPAN OVERVIEW
17.175: JAPAN OVERVIEW
17.176: JAPAN OVERVIEW
17.177: JAPAN OVERVIEW
17.178: JAPAN OVERVIEW
17.179: JAPAN OVERVIEW
17.180: LOCAL MARKET ANALYSIS - JAPAN
17.181: AUSTRALIA OVERVIEW
17.182: AUSTRALIA OVERVIEW
17.183: AUSTRALIA OVERVIEW
17.184: AUSTRALIA OVERVIEW
17.185: AUSTRALIA OVERVIEW
17.186: AUSTRALIA OVERVIEW
17.187: AUSTRALIA OVERVIEW
17.188: AUSTRALIA OVERVIEW
17.189: LOCAL MARKET ANALYSIS - AUSTRALIA
17.190: INDONESIA OVERVIEW
17.191: INDONESIA OVERVIEW
17.192: INDONESIA OVERVIEW
17.193: INDONESIA OVERVIEW
17.194: INDONESIA OVERVIEW
17.195: INDONESIA OVERVIEW
17.196: INDONESIA OVERVIEW
17.197: INDONESIA OVERVIEW
17.198: LOCAL MARKET ANALYSIS - INDONESIA
17.199: MALAYSIA OVERVIEW
17.200: MALAYSIA OVERVIEW
17.201: MALAYSIA OVERVIEW
17.202: MALAYSIA OVERVIEW
17.203: MALAYSIA OVERVIEW
17.204: MALAYSIA OVERVIEW
17.205: MALAYSIA OVERVIEW
17.206: MALAYSIA OVERVIEW
17.207: LOCAL MARKET ANALYSIS - MALAYSIA
17.208: REST OF APAC OVERVIEW
17.209: REST OF APAC OVERVIEW
17.210: REST OF APAC OVERVIEW
17.211: REST OF APAC OVERVIEW
17.212: REST OF APAC OVERVIEW
17.213: REST OF APAC OVERVIEW
17.214: REST OF APAC OVERVIEW
17.215: REST OF APAC OVERVIEW
17.216: LOCAL MARKET ANALYSIS - REST OF APAC
17.217: MIDDLE EAST/AFRICA OVERVIEW
17.218: MIDDLE EAST/AFRICA BY COUNTRY
17.219: SAUDI ARABIA OVERVIEW
17.220: SAUDI ARABIA OVERVIEW
17.221: SAUDI ARABIA OVERVIEW
17.222: SAUDI ARABIA OVERVIEW
17.223: SAUDI ARABIA OVERVIEW
17.224: SAUDI ARABIA OVERVIEW
17.225: SAUDI ARABIA OVERVIEW
17.226: SAUDI ARABIA OVERVIEW
17.227: LOCAL MARKET ANALYSIS - SAUDI ARABIA
17.228: UAE OVERVIEW
17.229: UAE OVERVIEW
17.230: UAE OVERVIEW
17.231: UAE OVERVIEW
17.232: UAE OVERVIEW
17.233: UAE OVERVIEW
17.234: UAE OVERVIEW
17.235: UAE OVERVIEW
17.236: LOCAL MARKET ANALYSIS - UAE
17.237: SOUTH AFRICA OVERVIEW
17.238: SOUTH AFRICA OVERVIEW
17.239: SOUTH AFRICA OVERVIEW
17.240: SOUTH AFRICA OVERVIEW
17.241: SOUTH AFRICA OVERVIEW
17.242: SOUTH AFRICA OVERVIEW
17.243: SOUTH AFRICA OVERVIEW
17.244: SOUTH AFRICA OVERVIEW
17.245: LOCAL MARKET ANALYSIS - SOUTH AFRICA
17.246: IRAN OVERVIEW
17.247: IRAN OVERVIEW
17.248: IRAN OVERVIEW
17.249: IRAN OVERVIEW
17.250: IRAN OVERVIEW
17.251: IRAN OVERVIEW
17.252: IRAN OVERVIEW
17.253: IRAN OVERVIEW
17.254: LOCAL MARKET ANALYSIS - IRAN
17.255: QATAR OVERVIEW
17.256: QATAR OVERVIEW
17.257: QATAR OVERVIEW
17.258: QATAR OVERVIEW
17.259: QATAR OVERVIEW
17.260: QATAR OVERVIEW
17.261: QATAR OVERVIEW
17.262: QATAR OVERVIEW
17.263: LOCAL MARKET ANALYSIS - QATAR
17.264: REST OF MEA OVERVIEW
17.265: REST OF MEA OVERVIEW
17.266: REST OF MEA OVERVIEW
17.267: REST OF MEA OVERVIEW
17.268: REST OF MEA OVERVIEW
17.269: REST OF MEA OVERVIEW
17.270: REST OF MEA OVERVIEW
17.271: REST OF MEA OVERVIEW
17.272: LOCAL MARKET ANALYSIS - REST OF MEA
18.0: COMPETITION OVERVIEW
18.1: MARKET SHARE ANALYSIS
18.2: MARKET REVENUE BY KEY COMPANIES
18.3: MARKET POSITIONING
18.4: VENDORS BENCHMARKING
18.5: STRATEGY BENCHMARKING
18.6: STRATEGY BENCHMARKING
19.0: GE Healthcare
19.1: GE Healthcare
19.2: GE Healthcare
19.3: GE Healthcare
19.4: GE Healthcare
19.5: Siemens Healthineers
19.6: Siemens Healthineers
19.7: Siemens Healthineers
19.8: Siemens Healthineers
19.9: Siemens Healthineers
19.10: Philips Healthcare
19.11: Philips Healthcare
19.12: Philips Healthcare
19.13: Philips Healthcare
19.14: Philips Healthcare
19.15: Canon Medical Systems
19.16: Canon Medical Systems
19.17: Canon Medical Systems
19.18: Canon Medical Systems
19.19: Canon Medical Systems
19.20: Hitachi Medical
19.21: Hitachi Medical
19.22: Hitachi Medical
19.23: Hitachi Medical
19.24: Hitachi Medical
19.25: Neusoft Medical Systems
19.26: Neusoft Medical Systems
19.27: Neusoft Medical Systems
19.28: Neusoft Medical Systems
19.29: Neusoft Medical Systems
19.30: Mediso Medical Imaging Systems
19.31: Mediso Medical Imaging Systems
19.32: Mediso Medical Imaging Systems
19.33: Mediso Medical Imaging Systems
19.34: Mediso Medical Imaging Systems
19.35: DDD-Diagnostic
19.36: DDD-Diagnostic
19.37: DDD-Diagnostic
19.38: DDD-Diagnostic
19.39: DDD-Diagnostic
19.40: SurgicEye
19.41: SurgicEye
19.42: SurgicEye
19.43: SurgicEye
19.44: SurgicEye
19.45: CMR Naviscan
19.46: CMR Naviscan
19.47: CMR Naviscan
19.48: CMR Naviscan
19.49: CMR Naviscan
19.50: Kromek Group
19.51: Kromek Group
19.52: Kromek Group
19.53: Kromek Group
19.54: Kromek Group
19.55: Gamma Medica
19.56: Gamma Medica
19.57: Gamma Medica
19.58: Gamma Medica
19.59: Gamma Medica
19.60: Capintec
19.61: Capintec
19.62: Capintec
19.63: Capintec
19.64: Capintec
19.65: Biosensors International Group
19.66: Biosensors International Group
19.67: Biosensors International Group
19.68: Biosensors International Group
19.69: Biosensors International Group
19.70: Blue Earth Diagnostics
19.71: Blue Earth Diagnostics
19.72: Blue Earth Diagnostics
19.73: Blue Earth Diagnostics
19.74: Blue Earth Diagnostics
19.75: Cardinal Health
19.76: Cardinal Health
19.77: Cardinal Health
19.78: Cardinal Health
19.79: Cardinal Health
19.80: Digirad Corporation
19.81: Digirad Corporation
19.82: Digirad Corporation
19.83: Digirad Corporation
19.84: Digirad Corporation
19.85: Eczacibasi-Monrol Nuclear Products
19.86: Eczacibasi-Monrol Nuclear Products
19.87: Eczacibasi-Monrol Nuclear Products
19.88: Eczacibasi-Monrol Nuclear Products
19.89: Eczacibasi-Monrol Nuclear Products
19.90: Fujifilm Holdings Corporation
19.91: Fujifilm Holdings Corporation
19.92: Fujifilm Holdings Corporation
19.93: Fujifilm Holdings Corporation
19.94: Fujifilm Holdings Corporation
562})

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings